Telling.ai
Telling.ai leverages advanced algorithms to analyze voice and breath sounds for assessing lung health, particularly focusing on chronic respiratory diseases. Their innovative approach allows for non-invasive monitoring of respiratory conditions, providing real-time feedback and personalized insights to users. By targeting the 47 million Americans at risk for chronic lung diseases, Telling.ai aims to reduce hospitalizations and improve patient outcomes through timely interventions. Their technology stands out due to its ease of use, low cost, and the ability to deliver instantaneous results, making it a valuable tool in telehealth respiratory monitoring.
Telling.ai
Telling.ai leverages advanced algorithms to analyze voice and breath sounds for assessing lung health, particularly focusing on chronic respiratory diseases. Their innovative approach allows for non-invasive monitoring of respiratory conditions, providing real-time feedback and personalized insights to users. By targeting the 47 million Americans at risk for chronic lung diseases, Telling.ai aims to reduce hospitalizations and improve patient outcomes through timely interventions. Their technology stands out due to its ease of use, low cost, and the ability to deliver instantaneous results, making it a valuable tool in telehealth respiratory monitoring.
TL;DR
What they do: AI analysis of voice and breath sounds to assess lung health and predict respiratory events
Product mode: Phone-based, non-invasive sample capture with real-time feedback
Headquarters: Pittsburgh, United States
Notable funding: Received a $1.0M NSF grant (March 2023) and has recorded seed-stage funding
Company Overview
Problem Domain
Chronic and acute respiratory disease monitoring (e.g., COPD, asthma); prediction and prevention of acute exacerbations.
Industry
Healthtech / Medical AI
Funding Track Record
1000000.00
NSF grant listed as $1.0M (March 2023)
310000.00
Total funding amount recorded as $310,000 with last funding date 2022-07-29
Investor Signal
“Innovation Works; AlphaLab Health”